Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations
Eiji Iwama(Kyushu University), Isamu Okamoto(Kyushu University Hospital), Junji Kishimoto(Kyushu University Hospital), Noriko Yanagitani(The Cancer Institute Hospital), Haruyasu Murakami(Shizuoka Cancer Center), Kōichi Goto(National Cancer Center Hospital East), Masahiro Morise(Nagoya University), Yoshitaka Zenke(National Cancer Center Hospital East), Tomohiro Sakamoto(Memorial Sloan Kettering Cancer Center), Haruko Daga(Osaka City General Hospital), Shingo Matsumoto(National Cancer Center Hospital East), Shunichi Sugawara(Sendai Kousei Hospital), Yoichi Nakanishi(RIKEN Center for Integrative Medical Sciences)
Cited by 77
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835